Zymeworks CEO Kenneth Galbraith and Daiichi Sankyo CEO Sunao Manabe

Dai­ichi and Zymeworks end an­ti­body pact af­ter sev­en years

Zymeworks and Dai­ichi Sankyo end­ed a sev­en-year col­lab­o­ra­tion on bis­pe­cif­ic an­ti­bod­ies last week.

Un­der the 2016 agree­ment, Zymeworks li­censed its Azy­met­ric and Efect plat­forms to Dai­ichi Sankyo to de­vel­op one bis­pe­cif­ic an­ti­body ther­a­py in ex­change for tech­nol­o­gy ac­cess fees and mile­stone pay­ments and roy­al­ties, ac­cord­ing to SEC fil­ings. But Zymeworks al­so got some­thing else in re­turn, in the form of li­cens­es to cer­tain im­muno-on­col­o­gy an­ti­bod­ies from Dai­ichi.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.